Short5 Cobenfy A New Approach to Schizophrenia Treatment

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=mMVT61Vp1Vc

Full video here: • Cobenfy A New Approach to Schizophren... • The sources discuss the FDA approval of Cobenfy (xanomeline and trospium chloride), a new drug for treating schizophrenia in adults. Cobenfy is the first antipsychotic drug with a new mechanism of action in several decades, targeting cholinergic receptors instead of dopamine receptors. The drug's approval marks a significant advancement in the field, offering a new treatment option for a condition that has historically been challenging to manage. • Cobenfy's journey to approval began with the rediscovery of xanomeline, a drug initially developed by Eli Lilly for Alzheimer's disease. While xanomeline showed promise in treating cognitive decline, it was plagued by significant side effects. Karuna Therapeutics, a subsidiary of PureTech Health, recognized the potential of xanomeline and licensed it from Lilly. They developed a unique combination of xanomeline with trospium chloride, a muscarinic receptor antagonist that acts outside the central nervous system. This combination, marketed as KarXT and later acquired by Bristol Myers Squibb, successfully mitigated the side effects while preserving the therapeutic benefits. • The FDA approval of Cobenfy is based on positive results from the EMERGENT clinical program, demonstrating statistically significant reductions in schizophrenia symptoms. The drug's safety and tolerability profile has been established across acute and long-term trials. While Cobenfy does come with some side effects, it does not carry the same warnings and precautions as atypical antipsychotics and does not have a boxed warning. The development and approval of Cobenfy highlight the importance of innovative approaches to drug discovery and offer hope for improved treatment options for individuals living with schizophrenia.

#############################

New on site